Cheston Ellis, APRN
Primary Care · El Reno, OKNPI 1720663057
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $334 of the $437 with a category attached, or 76.4%. It is spread thinly across 15 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $202, 3.1 times the $65 reported in 2021.
Across 20 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$76
- Currax Pharmaceuticals LLC$50
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$49
- AstraZeneca$43
- Dexcom, Inc.$30
- Organon$28
- plus $160 from 9 others
What the payments were for
- Food & beverage$33476%
- Education$5011%
- Other$5312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 2 | $76 |
| Currax Pharmaceuticals LLC | 2 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $49 |
| AstraZeneca | 2 | $43 |
| Dexcom, Inc. | 2 | $30 |
| Organon | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $22 |
| Mannkind Corporation | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Boston Scientific | 1 | $18 |
| AbbVie | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Pfizer | 1 | $14 |
| Novo Nordisk | 1 | $12 |
How this compares
$437 in reported general payments places this provider in the 55th percentile of 83 primary care providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 38 | $39,155 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,072 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,977 |
| Ventolin HfaAlbuterol Sulfate | 27 | $1,561 |
| Levothyroxine Sodium | 40 | $561 |
| Nebivolol Hcl | 20 | $548 |
| Omeprazole | 27 | $505 |
| Montelukast Sodium | 13 | $448 |
| Rosuvastatin Calcium | 33 | $412 |
| Losartan Potassium | 28 | $406 |
| Atorvastatin Calcium | 23 | $344 |
| Pravastatin Sodium | 12 | $330 |
| Pantoprazole Sodium | 15 | $316 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $277 |
| Escitalopram Oxalate | 13 | $243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere | $43 | $7,07211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 83 primary care providers in Oklahoma.
Other primary care in El Reno
- Amber MaharSallisaw$9K
- Misty DeanOklahoma City$6K
- Melissa GingerichClaremore$6K
- Cristina SarrosaTulsa$6K
- Tamara ManningNorman$5K
- Jessica KearneyOklahoma City$5K
- Erin OlmstedOklahoma City$3K
- Divya JoykuttyOklahoma City$3K
- Stephanie PennieTulsa$3K
- Steven OrtmanTulsa$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.